Therapeutics News and Research

RSS

Making Complex Cell Culture Easy and Efficient with AI

Molecular Devices' CellXpress AI streamlines cell culture processes, reducing human error and improving efficiency in drug discovery with advanced automation.

From Molecular Devices UK Ltd 12 Mar 2025

Shift Biosciences announces key appointments to advance rejuvenation therapeutics pipeline

Shift Biosciences, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Jill and Laurence will guide Shift in building a robust product translation and business development strategy respectively, enabling the Company to capitalize on early momentum and progress its pipeline of novel rejuvenation therapeutics towards clinical development.

12 Mar 2025

New approach shows promise for uncovering potential sepsis treatments

The immune system typically can ramp up the body's defenses to clear out an invading threat without issue.

11 Mar 2025

New automated system revolutionizes drug evaluation in zebrafish

Preclinical drug evaluation, especially for cardiotoxicity, is a critical stage in the drug development process.

11 Mar 2025

Novel regulators in digestive tract disease progression and treatment

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive tract diseases, positioning these molecules as potential biomarkers for diagnosis, prognosis, and targeted therapies. The comprehensive review explores the biogenesis, classification, and biological functions of tsRNAs, shedding light on their influence over cellular processes such as translation regulation, epigenetic modification, and protein interactions.

11 Mar 2025

Study reveals the role of transcription factors as therapeutic gateways in MAFLD

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions worldwide. This complex liver disorder ranges from simple steatosis to more severe forms, including metabolic dysfunction-associated steatohepatitis (MASH), which may progress to fibrosis, cirrhosis, and even liver cancer.

11 Mar 2025

Decoding programmed cell death in breast cancer

This review highlights the critical role of ubiquitin-specific proteases (USPs) in regulating programmed cell death (PCD) in breast cancer (BC). As the most prevalent malignant tumor among women, BC remains a significant global health challenge.

11 Mar 2025

Study highlights the role of ELF4 as a key transcription factor in development, immunity, and oncology

ELF4, a transcription factor belonging to the ETS family, has emerged as a pivotal regulator in cell differentiation, immune system function, and cancer progression. This newly published review underscores its molecular complexity and clinical significance, shedding light on its dual role in tumor suppression and oncogenesis.

11 Mar 2025

Deciphering the tumor-immune interplay in endometrial carcinoma

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most prevalent gynecological cancers, EC continues to challenge researchers and clinicians due to its dynamic interaction with the immune microenvironment.

11 Mar 2025

Study reveals TCM-Based strategies for ferroptosis modulation

Innovative insights into the role of ferroptosis, a unique form of programmed cell death, are reshaping the landscape of disease treatment. This growing field highlights how Traditional Chinese Medicine (TCM) can effectively modulate ferroptosis, offering novel therapeutic approaches for various conditions, including cancer, cardiovascular diseases, neurodegenerative disorders, and organ injuries.

11 Mar 2025

Harnessing lncRNAs for early diagnosis and intervention in acute kidney injury

A new review published in Genes & Diseases on long non-coding RNAs (lncRNAs) highlights their critical role in the development, diagnosis, and potential treatment of acute kidney injury (AKI) and chronic kidney disease (CKD). The findings emphasize the importance of exosomal lncRNAs, which function as molecular regulators in kidney pathology and hold promise for future biomarker discovery and therapeutic advancements.

11 Mar 2025

Can microbiome discoveries finally become treatments? Scientists show the way

Researchers propose a novel iterative strategy combining big data and experimental models to move microbiome research from theory to clinical applications. The study highlights the need to bridge the gap between correlation and causation to develop effective microbiome-based therapies.

9 Mar 2025

Understanding the role of LSD1 in cellular processes and disease

A new review highlights the pivotal role of LSD1 (lysine-specific demethylase 1) in regulating critical cellular processes and its implications for human diseases.

8 Mar 2025

Unraveling the genetic differences between LUAD and LUSC in lung cancer

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small cell lung cancer (NSCLC).

8 Mar 2025

Circular RNA plays key role in cancer biology and therapy

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

8 Mar 2025

Vanderbilt researchers aim to use AI to develop antibody therapies for any target

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

8 Mar 2025

Ubiquitination plays a key role in cancer stem cell function and treatment resistance

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), shedding light on potential therapeutic targets for combating tumor progression, recurrence, and drug resistance.

8 Mar 2025

EZH2 inhibition offers hope for fighting treatment-resistant cancers

The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases.

8 Mar 2025

Breakthrough drug more than doubles survival in glioblastoma patients

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults.

7 Mar 2025

Insilico Medicine's AI-driven drug Rentosertib receives official generic name

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF) – Rentosertib (formerly known as ISM001-055) – has been granted an official generic name by the United States Adopted Names (USAN) Council.

7 Mar 2025